

84. A method of determining the difference between the coronary blood flow through disease free coronary vessels and stenotic coronary vessels in a human comprising the steps of:

- 12
- (a) administering to said human an amount of an adenosine receptor agonist sufficient to provide coronary artery dilation;
 - (b) performing a method for measuring coronary blood flow velocity on said human in order to assess the vasodilatory capacity (reserve capacity) of disease free coronary vessels as opposed to stenotic coronary vessels.

REMARKS

Reconsideration of this application as amended is respectfully requested.

Claims 22 to 68 are pending in this application. Claims 22, 23, 24, 27, 29, 30, 38, 39, 42, 43, 44, 46, 49, 50, 53, 54, 55, 58, 59, 62, 65 and 66 have been amended. Claims 25, 26, 28, 40, 41, 51, 52, 60, 61, 63 and 64 have been cancelled. Claims 69 to 84 have been added.

Attorney for Applicants gratefully acknowledge the personal interview held between the undersigned and the Examiner on June 5, 1991. At the interview the pending Office Action as well as the references relied on by the Examiner were discussed. It was agreed that all the pending claims would be allowed if the dosage ranges were incorporated into the independent claims. While applicants believe that this is not necessary to overcome the references cited by the Examiner, they have agreed to this amendment to further the prosecution of the present application. Thus, applicants have amended independent claims 22, 38, 49 and 58 to incorporate administering by an intravenous route to a

human about 20 mcg/kg/minute to about 200 mcg/kg/minute of an adenosine receptor agonist sufficient to provide coronary artery dilation. Applicants have also added new independent claims 69, 72, 74, 75, 77, and 78 which concern administering to a human by an intracoronary route about 2 mcg to about 20 mcg of adenosine or an adenosine receptor agonist. Applicants reserve the right to file a continuation application for subject matter encompassed by the present application but not included within the claims allowed in the present form. Applicants have added new independent claims 81 to 84 to encompass this subject matter. New claims 81 to 84 will be cancelled and included in a continuation application when a notice of allowance is issued for the claims pending in the present application.

Based on the interview held between the undersigned and the Examiner, applicants respectfully submit that the claims of the present application are in condition for allowance. Applicants request an expedited notice of allowance for these claims.

Date: June 11, 1991

Respectfully submitted,

Gerald J. Flintoft 20,823
Gerald J. Flintoft (Reg. No.)
By Valentin A. Argu Reg. No. 32,823
PENNIE & EDMONDS
1155 Avenue of the Americas
New York, New York 10036-2711

(212) 790-9090